Shareholders back Mast Therapeutics' merger with Savara, but quorum not yet there for tomorrow's special meeting, adjournment looms

|About: Savara Inc. (SVRA)|By:, SA News Editor

Mast Therapeutics (MSTX -1.4%announces that it may have postpone tomorrow's special meeting of stockholders to vote on its planned merger with Savara if it fails to obtain a quorum of more than 50% of its outstanding shares. Currently, ~44% of shares have been voted, more than 90% in favor of the transaction.

CEO Brian Culley is urging the firm's 30K stockholders, many with small positions, to step forward and vote.

Previously: Mast Therapeutics and Savara to merge in all-stock deal (Jan. 8)